Outcome of Intravitreal Dexamethasone Implant Use in Uveitic Eyes Undergoing Pars Plana Vitrectomy Surgery

Ocul Immunol Inflamm. 2021 Aug 18;29(6):1126-1131. doi: 10.1080/09273948.2020.1726970. Epub 2020 Mar 6.

Abstract

Purpose: To report the outcomes in eyes with noninfectious uveitis receiving dexamethasone implant at the time of pars plana vitrectomy (PPV).Methods: Retrospective analysis of visual acuity (VA), intraocular pressure (IOP), vitreous haze score (VHS), and central subfield thickness (CST) at baseline and follow-up visits.Results: Fourteen eyes received dexamethasone implant at the time of PPV. The CST was improved from 469 ± 182 µm at baseline to 320 ± 60 at 6 months (p = .0112) and 295 ± 46 at 12 months (p = .0728). Vitritis only recurred in 2 eyes at 6 months (18.2%) and 1 eye at 12 months (14.3%). The probability of VA improvement of ≥0.3 logMAR was 57% at 6 months and 66% at 12 months. Therapy for IOP rise was initiated in 6 eyes (42.9%).Conclusions: Local delivery of dexamethasone implant with PPV is a feasible method to counteract postoperative inflammation and macular thickening.

Keywords: Dexamethasone Implant; PPV; uveitis; vitrectomy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Dexamethasone / administration & dosage*
  • Diabetic Retinopathy / surgery
  • Drug Implants*
  • Epiretinal Membrane / surgery
  • Female
  • Glucocorticoids / administration & dosage*
  • Humans
  • Intraocular Pressure / physiology
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Panuveitis / diagnostic imaging
  • Panuveitis / drug therapy*
  • Panuveitis / physiopathology
  • Phacoemulsification
  • Retinal Vein Occlusion / surgery
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Visual Acuity / physiology
  • Vitrectomy*

Substances

  • Drug Implants
  • Glucocorticoids
  • Dexamethasone